Jim Cramer commented on Occidental Petroleum (NYSE: OXY), stating that the stock's performance is heavily tied to geopolitical conflicts, suggesting it would decline significantly if wars ended. He explained that OXY acts as a proxy for crude oil prices, rallying hard when oil goes up and getting "pulverized" when it falls. Cramer highlighted that despite oil's recent rise, only a few oil plays, including OXY, were among the S&P's top performers.

Jim Cramer highlighted TJX Companies (NYSE: TJX) on Mad Money, noting that the off-price retailer thrives when consumers trade down during economic difficulties. He emphasized that TJX's success isn't just about low prices but rather its ability to offer quality goods at great value due to a wide selection from full-priced outlets offloading inventory. Cramer suggested that while many companies struggle, TJX maintains traction by providing valuable items in hard times.

Insmed (NASDAQ:INSM) is analyzed as a promising healthcare stock, ranking highly among non-AI stocks favored by billionaire Stanley Druckenmiller. The article details Insmed's strong product performance with Brinsupri and Arikayce, and highlights a robust pipeline, particularly TPIP, which has significant sales potential. Despite the positive outlook, the piece suggests that AI stocks might offer even greater returns.

United Rentals (URI) stock has significantly outperformed the Nasdaq Composite ($NASX) over the past three months, year-to-date, and the last 52 weeks. The company's strong performance was bolstered by robust Q1 2026 results, including record rental revenue and raised guidance, driven by increased fleet size and productivity. Despite this strength, analysts maintain a "Moderate Buy" rating, with the stock trading above its mean price target.

SLB OneSubsea has secured an engineering, procurement, and construction contract from BP to supply a subsea boosting system for the Thunder Horse development in the deepwater US Gulf. This award follows similar contracts for BP's Kaskida and Tiber developments, utilizing the same standardized high-pressure system. SLB OneSubsea is a joint venture formed by SLB, Aker Solutions, and Subsea 7.

Incyte plans to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for an upfront payment of $1.25 billion, with potential milestones up to an additional $750 million. The acquisition gives Incyte control of VGA039, an experimental once-monthly, under-the-skin injection in late-stage testing for von Willebrand disease, the most common inherited bleeding disorder. This move is part of Incyte CEO Bill Meury's strategy to diversify the company's portfolio as its main revenue-generating drug, Jakafi, faces patent expiration.

Assurant Inc. has attracted investor attention due to its solid recent quarterly results and ongoing capital returns through share repurchases and dividends. The company operates a specialty insurance and services model focused on lifestyle and housing protection, with its business driven by products for mobile devices, vehicles, and housing. Its performance is influenced by macroeconomic conditions and consumer spending on big-ticket items, offering investors exposure to traditional insurance underwriting and fee-based service revenues.

Biogen has agreed to a $18.9 million settlement with investors who alleged the company misled them about the commercial readiness of its Alzheimer's drug, Aduhelm. The lawsuit, filed in 2022, claimed Biogen made false statements regarding Medicare coverage and pricing of the drug, which faced controversy and limited use after its accelerated FDA approval. Biogen continues to deny wrongdoing, and the proposed settlement still requires court approval.

KeyCorp raised its Q2 2026 EPS estimate for Diamondback Energy to $5.63 from $5.20 and reiterated an Overweight rating with a $225 price objective, driving renewed investor interest. The Permian Basin-focused oil and gas producer continues to attract attention for its strong free cash flow generation, disciplined capital spending, and commitment to shareholder returns through dividends. Diamondback's operational efficiency and liquids-heavy production in the Permian Basin are key factors contributing to its strong performance and positive analyst sentiment.

JP Morgan analyst John Stansel maintained a "Neutral" rating for Centene (CNC) and raised its price target from $52.00 to $60.00. GuruFocus indicates that Centene is currently undervalued by approximately 25.2% with a GF Value™ of $83.82 against a current price of $62.67. Despite a strong GF Score™ of 73/100, its growth rank is low at 2/10, suggesting potential challenges in expanding revenue streams, though profitability and valuation are above average.